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leading to type two diabetes
R Maldonado-Ruiz1,2, L Montalvo-Martínez1,3, L Fuentes-Mera3 and A Camacho1,3
Obesity is an energy metabolism disorder that increases susceptibility to the development of metabolic diseases. Recently, it has
been described that obese subjects have a phenotype of chronic inﬂammation in organs that are metabolically relevant for glucose
homeostasis and energy. Altered expression of immune system molecules such as interleukins IL-1, IL-6, IL-18, tumor necrosis factor
alpha (TNF-α), serum amyloid A (SAA), and plasminogen activator inhibitor-1 (PAI-1), among others, has been associated with the
development of chronic inﬂammation in obesity. Chronic inﬂammation modulates the development of metabolic-related
comorbidities like metabolic syndrome (insulin resistance, glucose tolerance, hypertension and hyperlipidemia). Recent evidence
suggests that microglia activation in the central nervous system (CNS) is a priority in the deregulation of energy homeostasis and
promotes increased glucose levels. This review will cover the most signiﬁcant advances that explore the molecular signals during
microglia activation and inﬂammatory stage in the brain in the context of obesity, and its inﬂuence on the development of
metabolic syndrome and type two diabetes.
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INTRODUCTION
Obesity is an important risk factor for the morbidity and mortality
associated with metabolic syndrome, type 2 diabetes mellitus,
hypertension, dyslipidemia, cancer, neurodegenerative diseases
and other non-communicable chronic diseases.1 In 2014, more
than 1.9 billion adults were overweight with a body mass index
(BMI) greater or equal to 25 kg m− 2 and over 600 million were
obese with a BMI greater or equal to 30 kg m− 2. In children under
age 5, 42 million worldwide were obese.2 It has been proposed
that increase in obesity is related to global trade liberalization,
economic growth and rapid urbanization, changing diets
and population lifestyles. Developing countries are the most
affected by obesity and are predicted to continue to be so in the
next years.2 Statistical analysis predicts that by 2025, global
obesity will reach a prevalence of 18% in men and 21% in
women.2 Therefore, the study of molecular mechanisms involved
in obesity is fundamental to tackle this major public health
problem.
Development of obesity requires a positive energy balance.
However, to date, it is not entirely clear why the expansion of
adipose tissue in obese individuals is strongly associated with
insulin resistance and diabetes.3 There are two main hypotheses
that try to explain this relationship. On one hand, this mechanism
could be the result of a change in the proportion of adipokines,
promoting insulin resistance.3,4 The second hypothesis suggests
that obesity promotes a failure of adipose tissue expansion
and function, resulting in the release of fatty acids, and their
transport and accumulation in peripheral organs such as skeletal
muscle, liver, beta cells or myocardium, a process known as
lipotoxicity.3,4 In this sense, the laboratory of Professor Vidal-Puig
and others have shown that the type of lipid differs in its degree
of toxicity, suggesting that certain species such as ceramides and
diacylglycerols promote more toxic effects.1,5 As an example, an
increase of up to 80% of free fatty acids (495 vs 887 μM), 112% in
triglycerides (86 vs 188 mg dl− 1), 38% in C18:0 (0.38 vs 0.26 μM)
and 20% in C24:1 (0.52 vs 0.43 μM) ceramides in plasma has been
demonstrated in obese humans versus lean humans.5,6 The data
also show increases of 76 and 83% in C16:0 (1 vs 4 μM) and C20:0
(0.1 vs 0.65 μM) ceramides in the muscle of obese subjects when
compared with thin humans, respectively.5–7 Of interest, a 50%
reduction in two phospholipids (phosphoethanolamine PE 16:0-
/20:4 and 18:1/20:4), and of 75% of ether lipids that contain
unsaturated fatty acids (0.06–0.03 mM and 0.03–0.01 mM) in
adipose tissue of morbidly obese identical twins, respectively, was
demonstrated.8 The alterations in the lipid proﬁle in obese
humans can be reproduced in animal models with genetic obesity
(ob/ob) or in obesity induced by a high-fat diet.9 In a second
study, genetic obesity increased triacylglycerols levels by 40%
(values of 18 mM) and long-chain fatty acids by 25% (values 1 μM)
(11). Meanwhile, a high-fat diet in mice generated an increase
of ~ 284% in ceramide C20 (values of 0.026 μM), and of C14,
C160, C18 (values of 0.26, 0.08, 0.04 μM, respectively) in plasma.10
In this same model, an increase of 100% in triglyceride levels
(values of 20 mM) was observed, long-chain fatty acids (values of
5 μM), ceramides (values 140 μM), and diacylglycerol (600 μM) in
muscle.10 Overall, obesity in humans promotes increased triacyl-
glycerol, ceramide and diacylglycerol levels that can be repro-
duced using animal models with genetic or nutritionally induced
obesity.
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LIPOTOXICITY IS A PATHOGENIC MECHANISM IN KEY ORGANS
FOR METABOLIC SYNDROME
The epidemiological data conﬁrm a strong relationship between
the increase in the degree of obesity and the development of
diabetes, indicating that for every kilogram of weight gained, at
the population level, there is a linear increase in the rate of
diabetes.11 There is experimental evidence in humans and animal
models that lipotoxicity, associated with increased lipids in
obesity, may cause alterations in pancreatic beta cell function,
and in skeletal and cardiac muscle, and can even induce hepatic
steatosis, contributing to the generation of insulin resistance and
type 2 diabetes.12,13 Meanwhile, lipotoxicity may also occur in the
CNS, as has been observed in several neurodegenerative
diseases.14,15 However, there is still not enough evidence to
conﬁrm the toxic damage caused by lipids to the CNS and their
participation in metabolic complications associated with insulin
resistance and type 2 diabetes. Thus, here we will review new
evidence, suggesting the role of inﬂammation in the central
nervous system during lipid accumulation on insulin sensitivity
leading to metabolic failure.
THE ROLE OF LIPOTOXICITY IN THE ACTIVATION OF
INFLAMMATION AND METABOLIC FAILURE
The immune response is seen as a defense mechanism against
infection; however, recent evidence has shown a strong relation-
ship between inﬂammation and metabolic disorders. It is known
that the immune response is involved in the balance and
maintenance of an adequate metabolic state; however, it can
have adverse effects under conditions of altered metabolic
demand.16 The metabolic imbalance can lead to overactivation
of the immune system, triggering a process of chronic inﬂamma-
tion, which has been observed in obesity and metabolic
syndrome.16,17 The ﬁrst evidence demonstrating the presence of
an inﬂammatory mechanism in diabetes was the pioneering
discovery of the Randle glucose-fatty acid cycle,18 who at the time
proposed as the ﬁrst mechanism, the development of insulin
resistance induced by fatty acids. This ﬁnding led to the
discoveries of the obesity gene (ob) and a number of hormones
derived from adipocytes such as leptin, adiponectin, and resistin,
and various pro- and anti-inﬂammatory molecules termed
adipokines, which redeﬁned the endocrine and metabolic
function of adipose tissue.19 These molecules have been shown
to have autocrine/paracrine effects locally as well as an endocrine
effect systemically, allowing them to act at the metabolically
relevant organs, including the brain, liver, muscle, adipose tissue
and pancreas.
It is well established that the increase in lipid concentrations in
plasma and their accumulation in select organs and adipose tissue
promotes inﬂammation and metabolic degeneration.19 However,
it is not fully elucidated which are the organs or systems
responsible for the inﬂammatory process during lipotoxicity. In
this context, some years ago, we demonstrated that adipose tissue
of mice exposed to high-fat diet showed macrophage recruitment
with a proinﬂammatory proﬁle and that this phenotype could be
reversed with PPAR gamma receptor activators, indicating active
lipogenesis in macrophages.20 With this, it is proposed that during
the development of obesity there is adipocyte hypertrophy as a
result of an increase in lipid-fat content and the presence of
activation of a proinﬂammatory response that could well be
extended to metabolically relevant organs.19 The molecular
mechanism of this activation promotes a failure in the regulation
of metabolic homeostasis, including intake and satiety, and the
synthesis and degradation of lipids and glucose, and so on. To
date, the presence of inﬂammation in various metabolically
relevant organs has been reported during increased lipids,
including skeletal muscle, liver, heart and pancreatic β-cells, which
overall contributes to the pathophysiology of insulin resistance,
fatty liver disease, impaired function of the myocardium and β-cell
insufﬁciency, respectively.
OBESITY AND METABOLIC SYNDROME, A CHRONIC
INFLAMMATORY PROCESS INDUCED BY AN IMBALANCE
IN ADIPOSE TISSUE HOMEOSTASIS AND INFILTRATING
IMMUNE CELLS
Originally, adipose tissue was considered simply as an organ at
rest that functioned as a reservoir in the form of triglycerides (TGA)
during over nutrition. During calorie restriction, lipase-dependent
adenylate cyclase (cAMP) hydrolyzes triglycerides and releases
free fatty acids (FFA) to meet the energy demands of the body.19
Research over the past two decades has revealed that adipose
tissue is a remarkably complex endocrine organ that serves as a
'master regulator' of systemic energy homeostasis.19 Recent
evidence has shown that fat cells communicate with the rest of
the body through the integration of nutritional and hormonal
signals, and by secreting a number of factors known as
adipokines. In recent years, great advances have been generated
in the identiﬁcation of adipokines and their functions, suggesting
that the role of adipose tissue is a priority in the development of
systemic inﬂammation. The importance of adipose tissue in
promoting inﬂammation in obesity and the metabolic syndrome
is evidenced by the presence of an inﬂammatory proﬁle that
correlates with macrophage inﬁltration in adipose tissue of mice
and obese humans with insulin resistance.21,22 The ﬁrst evidence
that linked the inﬂammatory process with obesity and metabolic
syndrome was the overexpression of tumor necrosis factor alpha
(TNF-α) in adipose tissue in obesity models in mice and rats, and in
adipose tissue and muscle in obese humans.23 Subsequently, was
showed a positive correlation between the degree of obesity and
hyperinsulinemia, and TNF-α levels and mRNA in adipose tissue.24
Additionally, molecular markers of inﬂammation have been
identiﬁed, including IL-1β, IL-6, IL-8, chemokine ligand 2 (CCL2),
CCL3, CCL5, adiponectin and acute-phase markers such as
C-reactive protein, serum amyloid A and ﬁbrinogen.25 All these
molecules coordinate inﬂammatory events in metabolically active
organs, such as the liver, skeletal muscle and adipose tissue, which
together contribute to the metabolic dysregulation and inﬂam-
mation observed in obesity and metabolic syndrome. The role that
each of these markers has in the development of inﬂammation
and metabolic damage are described below.
Tumor necrosis factor alpha (TNF-α)
TNF-α is a proinﬂammatory cytokine produced by a wide variety of
cells, mainly macrophages and lymphocytes. In turn, in the
endothelium and smooth muscle, TNF-α promotes the expression
of proinﬂammatory genes that are dependent on a transcription
factor called nuclear factor kappa-B (NF-kB). NF-kB is a process
mediated by activation of the c-Jun N-terminal kinase (JNK),
protein kinase C (PKC), and kinase subunit beta factor kappa-B
inhibitor (IKKβ).23,26–28 Meanwhile, at the ﬁnal stage, these
proteins stimulate transcription of the TNF-α gene, promoting
positive feedback to the inﬂammatory cascade.
In conditions of obesity, the increase in plasma levels of TNF-α
activates the PKC, IKKβ and JNK kinases, which consequently
phosphorylate serine residues of the protein substrate of the
insulin receptor (IRS), blocking downstream activation of the
pathway, a molecular pathological event known as insulin
resistance.29 It is known that TNF-α production originates from
resident macrophages in adipose tissue.27 TNF-α is a key molecule
in the activation of the inﬂammatory cascade that promotes
expression of molecular targets that are downstream from its
receptor, among which the increase in NF-κB expression is
notable. It is known that, in obese individual, macrophages are
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in a proinﬂammatory M1 state and show increased expression of
NF-κB, a decrease of the inhibitor of NF-κB (IκB) inhibitor and
consequently an increase in gene transcription of the inﬂamma-
tory response.30
Interleukin-6 (IL-6)
Interleukin-6 is a cytokine produced by many cell types such as
ﬁbroblasts, endothelial cells, monocytes and adipocytes. In
adipose tissue, production of IL-6, like TNF-α, is higher in visceral
adipose tissue in obesity and metabolic syndrome.31 One of the
main actions of IL-6, is control of the liver's production of
inﬂammatory molecules such as C-reactive protein (CRP), whose
circulating levels are a risk marker for cardiovascular events. There
is a strong correlation between the protein content of IL-6 in
adipose tissue and circulating levels of CRP.32 In addition, IL-6
plays a central role in the relationship between obesity,
inﬂammation, and coronary heart disease; in fact, intra- abnominal
visceral adipose tissue can produce greater amounts of IL-6 than
subcutaneous adipose tissue,32 proving that central obesity
increases cardiovascular risk in humans. Moreover, the production
of IL-6 by adipose tissue could directly affect liver metabolism by
inducing secretion of VLDL and hypertriglyceridemia, through the
portal venous system.32 Similarly, the action of this cytokine
inhibits phosphorylation of the substrate of insulin receptor 1 and
2 (IRS 1 & IRS2) and blocks the synthesis of hepatic glycogen
which results in insulin resistance.
C-reactive protein (CRP)
CRP is an acute-phase inﬂammatory protein used as a marker in
clinical practice to assess systemic inﬂammation, especially
in situations of infection. In addition, it has also been seen as a
risk marker for cardiovascular disease.33 This protein has been
shown to be an enhancer of inﬂammation in ischemic myocar-
dium by local complement activation, leading to the development
of myocardial infarctions and the length of these.34 Recently, a
positive correlation between the concentrations of CRP and body
mass index (BMI)35 has been found, in addition to IL-6 levels in
adipose tissue.32
Interleukin 1 beta (IL-1β)
IL-1β is a major proinﬂammatory cytokine, mainly produced by
macrophages. It has been found that this cytokine is increased in
adipose tissue, where its release has been greater in obesity.36
Normally, insulin action requires activation of the substrate of
insulin receptor 1 (IRS1), a component that is essential for
activating PI3K in response to insulin; this leads to phosphoryla-
tion of protein kinase B (also known as AKT), which results in an
increase of GLUT4 transporters in the plasma membrane that
maintain glucose homeostasis. However, it has been reported that
overexpression of IL-1β in primary human adipocytes and in 3T3-
L1 mice adipocytes causes decreased expression of the proteins:
IRS1, p85 PI3K, AKT and glucose transporter GLUT4. The
consequence of this effect is suppression of the signal transduc-
tion pathway of insulin, affecting glucose transport and fatty acid
oxidation. Additionally, this interleukin can also act on pancreatic
beta cells, inducing apoptosis through the activation of NF-κB.
Moreover, blockage of IL-1β production reduces hyperglycemia
and tissue inﬂammation.36,37 In a recent study, it was demon-
strated that a high content of fatty acids increases the production
and secretion of IL-1β, IL-6 and IL-8 via activation of the
inﬂammasomes NLRP3,38 and induces the development of obesity
and insulin resistance. This ampliﬁcation of cell damage is
associated with the production of IL-1β, and activates the
expression of more than 30 cytokines and chemokines, including
CSF3, CXCL1, CXCL2, CXCL12, MCP-1, IL-8, IP-10, MIP-1α and
MCP-4.39 In conclusion, the diverse action of IL-1β promotes the
development of obesity and insulin resistance.
Interleukin-8 (IL-8)
Serum levels of IL-8 correlate with liver inﬂammation and degree
of nonalcoholic fatty liver disease resulting from the accumulation
of free fatty acids in that organ as a consequence of obesity.40
Inﬂammasome NLPR3
Inﬂammasomes are cytoplasmic multiprotein complexes that are
part of the components of innate immunity, which is the ﬁrst line
of adaptive defense. The inﬂammasome that has been best
characterized to date is NLRP3, whose activation induces
conformational changes that allow recruitment of the adapter
protein ASC, which in turn interacts with inactive procaspase-1,
through the CARD domain, present in both proteins. Finally,
activated caspase-1 is responsible for the maturation of pro-IL-1β
and pro-IL-18, to obtain the biologically active forms, IL-1β and
IL-18, and more recently, IL-6 and IL -8.40,41
Its relationship with obesity emerges from a recent study, which
demostrated that obesity induces the assembly of inﬂammasome
NLRP3 by macrophages in adipose tissue, which mediates insulin
resistance and early type 2 diabetes as mentioned before.42 This
may be due to the presence of lipid molecule ceramide, which is
generated by macrophages from free fatty acids.42 In mice with a
free feed normal diet, it was found that increased expression of
both NLRP3 and IL-1β in visceral adipose tissue correlates directly
with body weight and adiposity compared to mice fed with a low-
calorie diet. These observations have also been seen in obese
humans, in whom weight loss is associated with decreased NLRP3
and IL-1β expression in subcutaneous adipose tissue. Moreover,
direct participation of NLRP3 in obesity has been conﬁrmed in
studies that have shown that in gene-deﬁcient mice fed with a
high-fat diet, activation of caspase-1 and expression of pro-IL-1b in
adipose tissue, and serum loss of IL-18 compared to the wild-type
phenotype is reduced. In addition, it was observed that mice
deﬁcient in NLRP3 and caspase-1, and fed a high-fat diet, are more
protected against insulin resistance.42
Adiponectin
Adiponectin is a 30 kDa protein that shares structural similarity
with collagen and TNF-α, and in which an anti-inﬂammatory effect
has been seen in endothelial cells that is capable of inhibiting the
proliferation of vascular smooth muscle cells, and suppressing
conversion of macrophages to foam cells.43 It is highly expressed
in adipose tissue and is present in the bloodstream in levels that
average 5–10 mg ml− 1 in humans. In obese subjects and patients
with coronary artery disease, plasma adiponectin levels are
signiﬁcantly below average and inversely related to body mass
index (BMI).44 This inverse relationship seems to be much greater
with respect to visceral fat in comparison with subcutaneous
peripheral fat. Co-cultures with visceral fat inhibit adiponectin
secretion by subcutaneous adipose tissue, suggesting that visceral
fat may secrete an inhibitor of adiponectin synthesis or
secretion.45 In this regard, some studies have found that TNF-α
exerts strong inhibition of promoter activity of adiponectin,46
which could explain the inverse relationship between visceral fat
and circulating adiponectin levels. This suggest an obvious
relationship that exists between obesity and low levels of
adiponectin in plasma, other research has linked low levels of
adiponectin with insulin resistance and type 2 diabetes.
Under basal conditions, adiponectin decreases insulin resistance
by increasing fatty acid oxidation, which reduces triglyceride (TG)
content in the muscle and liver. However, during obesity,
increased lipid reserves in insulin target tissues, such as muscle
and liver, are generated, leading to insulin resistance.47 This, as a
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result of adipocyte hypertrophy and alteration of its adipokine
secretory proﬁle, among which TNF-α and macrophage inﬁltration
in adipose tissue produce these and other major interleukins
(Interleukin-6 IL-6), for the development of inﬂammation and
metabolic failure. This is again conﬁrmed when the reduction in
macrophage activity and TNF-α production in vitro is observed
when treated with adiponectin, by inhibiting the signaling
pathway of NF-κB.46
CC chemokines (CCL2, CCL3, CCL5)
Chemokines are small proteins that originally were demonstrated
to direct movement of circulating leukocytes to sites of
inﬂammation or injury by chemotaxis and also that they were
capable of producing inﬂammatory mediators. CCL2 is a
chemokine that belongs to the family of CC chemokines, in which
two cysteine residues are adjacent to each other.48 This
chemokine has been associated with macrophage inﬁltration in
adipose tissue of obese mice models and in humans with
obesity.49 In addition to CCL2, it is known that there is
overexpression of other chemokines and their receptors (CCR2,
CCR3, CCR5), in adipose tissue subculture of obese subjects.48
Macrophage inﬂammatory protein-related protein-2 (MRP-2), a
member of the family of CC chemokines was one of the ﬁrst
potent chemoattractants for monocytes, lymphocytes, neutrophils
and eosinophils. It was found that MRP-2 levels were increased in
mice that were fed high-fat diets as well as in patients with human
atherosclerosis,48 indicating that MRP-2 could be associated with
the pathological inﬂammatory process related to obesity. More-
over, it has been reported that the macrophage inﬂammatory
protein-1 alpha (MIP-1α or CCL3) and the protein CCL5, which also
belongs to the chemokines, inﬂuence adipocyte function. In
particular, they function as macrophage recruitment factors, and
may be a crucial link between chemokines, adipose tissue
inﬂammation and insulin resistance.48,49 Both chemokines alter
lipid accumulation and leptin secretion by adipocytes. In fact, it
has been demonstrated that the gene expression of CCL5, CCL7,
CCL8 and CCL11 increases in visceral adipose tissue of subjects.49
Taken together, these chemokines are expressed in visceral
adipose tissue and adipose tissue subcultures of obese subjects,
playing an important role in promoting inﬂammation of adipose
tissue in obesity.
Serum amyloid A (SAA)
SAA is an inﬂammatory protein codiﬁed by the SAA1 and SAA2
genes that appear to be expressed in a coordinated manner. Its
transcription can be induced by glucocorticoids and various
cytokines such as TNF-α, IL-1α, IL-1β and IL-6.50,51 It has been
regarded as an autocrine ampliﬁer of the proinﬂammatory
environment because it stimulates the expression of the same
cytokines that activate it (IL-6, IL-8, and CXCL1).52 SAA is expressed
in adipose tissue, and its expression is increased greatly in obesity;
circulating levels of SAA show a positive correlation with insulin
resistance in obesity and type 2 diabetes.53,54 Furthermore, SAA
induces the production of IL-8 through the formyl peptide
receptor, FPRL1, and also activates NF-κB. The same signaling
pathway has been demonstrated as an important mediator of
inﬂammation associated with insulin resistance.
Fibrinogen
Fibrinogen is a dimeric glycoprotein found in plasma and in the
alpha granules of platelets. It is a precursor of ﬁbrin, whose
importance lies in the formation of blood clots in the presence of
wounds. In pathological conditions, it can result in the formation
of obstructive thrombi in the circulation, increasing the risk of
cardiovascular disorders, especially in obese subjects.54
CENTRAL INFLAMMATION AND MICROGLIA ACTIVATION
MODULATE PATHOLOGICAL NEURONAL PRUNING AND
COGNITIVE DEFICITS
The role of neuroinﬂammation and pathological microglia
activation on neuronal function, development and behavior have
been focused on intensive research in the last years. Elegant
studies have shown that microglia coordinates pruning of
synapses during development shaping proper neuronal circuit
structure and synaptic function.55 Under non pathological
scenario, microglia inﬁltration into the brain during development
leads to synaptic pruning and brain maturation. Synaptic pruning
is supported by the classical complement cascade, a key
component of innate immune pathogen defense, where microglia
suffers changes in morphology that correlate with its phagocytic
activity and receptor recognition. Proper synaptic pruning requires
the CR3 ligand complement 3 interactions. CR3 is a human cell
surface receptor, which consist of a differentiation molecule 11b
(CD11b) and CD18, and is found on polymorphonuclear leuko-
cytes, NK cells and mononuclear phagocytes like macrophages
and microglia cells.56,57 Recent evidence has shown that primary
deﬁcit in microglia such as deﬁcient of complement receptor 3
(CR3) was sufﬁcient to induce some autism-related behavioral and
functional connectivity deﬁcits.58 Also, pathological CR3-
dependent synaptic pruning might occur during inﬂammatory
neuropathologies such as stroke, trauma and neurodegenerative
diseases. Under this scenario, microglial CR3 triggers long-term
synaptic depression, which requires activation of nicotinamide
adenine dinucleotide phosphate oxidase (NADPH oxidase), and
GluA2-mediated A-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid receptor (AMPAR) internalization.59 Cognitive impairment
and behavioral alterations related to microglia activation and
synaptic pruning has also been reported during aging. Mouse
deﬁcient of progranulin gene, which is a genetic cause of
frontotemporal dementia, displays profound microglia inﬁltration
and synapses loss in the ventral thalamus, which correlates with
hyperexcitability and grooming behaviors.60 Microglia activation
and central inﬂammation might also be target of an external
stimulus such as a virus. Synaptic elimination by microglia CR3
receptor-dependent has been reported in a mouse model infected
with West Nile virus, leading to cognitive dysfunction and
neurocognitive impairment.61 Finally, a transcriptomic study
analyzing the Alzheimer’s Disease Risk Genes support the role of
inﬂammation as a leading cause of the pathology showing
immune response genes (CLU, CR1, ABCA7, MS4A, CD33 and
EPHA1).62 These evidences suggest that microglia CR3-dependent
synaptic pruning during development is a physiological pathway
shaping efﬁcient neuronal circuit structure and synaptic function.
However, pathological microglia CR3-dependent synaptic pruning
may also occur by internal (see below) as external stimuli, leading
to failure in neuronal excitability and memory and behavioral
alterations. In any case, it remains to be address if microglia
activation is a primary cause or a secondary consequence of
neuronal deﬁcits in humans and if it is exacerbated during
lipotoxic insult such as obesity or metabolic syndrome. We will
address this question below.
INFLAMMATION OF THE NERVOUS SYSTEM DURING OBESITY
IS KEY IN THE GENERATION OF METABOLIC DAMAGE AND
DIABETES
Substantial evidence has shown that chronic inﬂammation in
obesity is not limited to adipose tissue, but invades borders that
are farther away, and can be detected in the central nervous
system. This inﬂammatory response can originate by the
recruitment of peripheral immune cells, mainly macrophages
and B cells to the SNC, which promotes the generation of
inﬂammation.63 The link between glucose intolerance and central
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inﬂammation was reported by Kumar M (2014), showing that in
the genetic diabetic model (db/db mice) displays increase in
mRNA and protein levels of key chemokines such as CXCL10,
CXCL1, CCL2, CCL5, CCL3 and G-CSF, and cytokines such as IL-1β,
TNF, IL-6, IFNγ and IL-1α compared to WT mice, suggesting that
metabolic compromise correlate with central immune response
activation despite hypercaloric state.64 Also, initial research by
Velloso´s group reported that speciﬁc low-grade chronic inﬂam-
mation modulates body glucose homeostasis, supporting that
hypothalamic TNFα administration to rats leads to hyperinsuline-
mia and insulin resistance in liver and skeletal muscle,65and also
generates pancreas dysfunction.66,67 Of note, these effect are
dependent on parasympathetic signals delivered by the vagus
nerve to pancreas or liver.68,69 Anatomically, hypothalamus
modulates plasma glucose by vagal innervation to liver, which
activates the gluconeogenesis program. Reports have shown that
efﬁcient insulin signaling in mediobasal hypothalamus blocks
gluconeogenesis.70,71 In this context, vagal innervation seems to
regulate pancreas and liver inﬂammation given that nerve
stimulation reduces intestinal inﬂammation in the gut, which
depend on the α7 nicotinic acetylcholine receptor.72 This suggest
that compromising vagal innervation/stimulation to pancreas and
liver might lead to inﬂammation; however, it is also possible that
central inﬂammation during obesity compromises vagal innerva-
tion/stimulation, promoting organ dysfunction and plasma
glucose increase.
The effect of peripheral recruitment of inﬂammatory inducers
has been reported during lipotoxic insult induced by high-fat diet
intake in mice. There is evidence of B lymphocytes recruitment
into the CNS leading to the production of a pathogenic IgG
antibody, which increases inﬂammatory cytokines and promotes
polarization of M2 macrophages to the proinﬂammatory pheno-
type M1, resulting in the generation of insulin resistance.73
Additionally, recent studies have demonstrated that ingestion of a
high saturated fat diet increases expression of inﬂammatory
cytokines in the hypothalamus without evidence of peripheral
inﬂammation, presumably regulated by microglia.74,75 Also, recent
evidence shows that high-fat diet feeding during 12–20 weeks
promote increase in plasma glucose levels, which correlates with
microglia activation in hypothalamus.76,77 The susceptibility of
CNS to inﬂammation during lipotoxicity is evidenced by a recent
work showing that 3 days of exposure to a high-fat diet is
sufﬁcient to promote gliosis and inﬂammation in the hypothala-
mus of rats, with no apparent changes in peripheral organs.78 In
fact, microglia activation proﬁle in paraventricular nucleus of
hypothalamus might be even programed during neonatal stage
exposed to high-fat diet and persist into adulthood.79 While the
molecular mechanism, which modulates recruitment of bone
marrow-derived monocytic cells to the hypothalamus has not
been descibed enterely, it has been reported that the chemokine
CX3CL1 (fractalkine) is expresed in mice hypothalamus by high-fat
diet exposed, leading to bone marrow-derived monocytic cells
accumulates and promoting obesity and glucose intolerance.79
These evidences indicate that hypothalamus seems to be an early
target of inﬂammation during positive energy balance and an
active node regulating the cross-talk between CNS to liver or
pancreas.
THE TLR-IKKβ-NF-κB PATHWAY IN THE DEVELOPMENT OF
TYPE 2 DIABETES
For some years, it has been known that members of the IKK/NF-κB
family have constitutive activity in the hypothalamus and can be
in turn activated by different effectors, including molecular
patterns associated with damage (DAMPs), molecular patterns
associated with pathogens (PAMPs), cytokines, chemokines,
neurotransmitters and so on, and that they modulate events of
synaptic plasticity, neurotransmission and neuroprotection, and in
the proliferation of neural stem cells.80 However, aberrant
activation of the IKK/NF-κB axis has been linked to selective
neuroinﬂammation and apoptosis independent of
neurodegeneraion.81 In the context of metabolic damage, it has
been shown that inhibition of the IKK/NF-κB axis using the
terpenoid (Rb1) reduces inﬂammation and leptin resistance in the
hypothalamus.82 Furthermore, it has also been shown that
lipotoxicity activates the proinﬂammatory axis IKKβ-NF-κB in the
hypothalamus, promoting the generation of insulin
resistance.83–85 In this regard, in an elegant study Li J et al.
demonstrated that activation of the IKKβ-NF-κB pathway during
obesity, decreases neurogenesis, increases cognitive deterioration
and degeneration of hypothalamic stem cells.86,87 The deteriora-
tion in neural proliferation and differentiation, observed in obese
mice, seems to be the result of excessive release of inﬂammatory
cytokines such as TNF-α and IL-1β, which occurs after the
activation of NF-κB, and it is also known that the IKKβ/NF-κB axis
is efﬁciently activated by positive feedback.86,87 With this, it seems
that the IKKβ/NF-κB axis is a negative modulator of metabolism
and is associated with cognitive impairment (see Figure 1).
The molecular mechanisms linked to the activation of CNS
inﬂammation in conditions of lipotoxicity and its role on diabetes
susceptibility are not entirely clear. However, it has been proposed
that saturated fatty acids (SFA) are able to induce heterodimeriza-
tion of Toll-like receptors 1 and 2 (TLR1 and TLR2), and
homodimerization of Toll-like receptor 4 (TLR4), and simultaneous
movement into the region of lipidic rafts, possibly by interaction
of SFA with hydrophobic pockets present in the extracellular
region of TLR's.88–90 This mechanism, promotes the expression of
inﬂammatory cytokines through activation of NF-κB, and endo-
plasmic reticulum stress in the hypothalamus of rodents.91,92 It is
known that activation of this pathway disrupts the mechanisms
linked to satiety and hunger, in part to those indicated in the
arcuate nucleus that coordinate orexigenic and anorexigenic
signals.90–92 In particular, the TLR-IKKβ-NF-κB pathway seems to
be a molecular center that induces activation of additional
proteins, among which the protein TANK-BINDING KINASE 1
(TBK1) stands out. TBK1 is a member of the family of IKK proteins
that are involved in the innate immune response, integrating
multiple signals induced by viral infections, modulate the
regulatory factor of interferon 3 (IRF3) and has been linked with
a variety of autoimmune diseases and cancer.93 TBK1 activates the
NF-κB complex by activating IKKβ.94 Initial reports has shown that
TBK1 induces phosphorylation of the serine residue 994 of the
insulin receptor, which correlates with insulin resistance in vivo
and in vitro model of metabolic compromise.95 Recent evidence
indicates that TBK1 may be a favorable drug target since inhibition
of the molecular binomial TBK1/IKK-ε prevents generation of type
2 diabetes mellitus in obese mice.96 In this context, our research
group has demonstrated that stimulation with saturated lipids
favorably activates TBK1 who translocates to the region of lipids
rafts in neurons of the hypothalamus of obese mice, which
correlates with insulin resistance.97 Of interest, the unpublished
data from our laboratory show that TBK1 is activated in microglia
and correlates with the release of proinﬂammatory cytokines such
as TNF-alpha and IL-6. Our data correlate with a recent study
showing that intrahypothalamic inhibition of IKKε decreases TNF-
alpha levels, improves insulin and leptin sensitivity, and decreases
food intake.98 The molecular binomial TBK1/IKKε seems to have
more versatile functions related to the regulation of body glucose
homeostasis. In a recent study, it was shown that inhibition of
TBK1/IKKε in obese mice induces the release of IL-6, which
stimulates phosphorylation of the Stat3 pathway in the liver,
suppressing gluconeogenesis.99
Overall, it is proposed that alterations in the control of glucose
levels and food intake may be linked to the activation of microglia
in the CNS through the TLR-IKKβ-NF-κB pathway.
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CENTRAL MODULATION OF INFLAMMATION AND MICROGLIA
ACTIVATION IMPROVE METABOLIC FAILURE AND COGNITIVE
IMPAIRMENT
Central modulation of inﬂammation during positive energy
balance seems to improve insulin resistance and metabolic failure.
Subcutaneous administration of liraglutide or canagliﬂozin, a
sodium-glucose cotransporter 2 (SGLT2) inhibitor, to obese
insulin-resistance mice blocks microglia activation in hypothala-
mus, which correlates with the recovery of insulin and glucose
homeostasis, and decrease of fat and triglyceride content.100,101
Also, the intracerebroventricular administration of the IKKβ/NF-κB
blocker, prevents hypothalamic inﬂamation and improves body
weight, fat accumulation and glucose, and energy homeostasis in
an diet-induced obese model.85,102,103 In addition to the
pharmacological modulation of inﬂammation in the CNS, physical
activity might decreases central inﬂammation. Exercise decreases
hypothalamic inﬂammation linked to IKKbeta pathway and
improves insulin and leptin sensitivity and cognitive impairment
in an obese rodent model.104
CONCLUSIONS
The lipotoxicity associated with obesity generates metabolic
disorders related to impaired glucose homeostasis. The molecular
pathways linked to this metabolic process propose central and
peripheral inﬂammation as a common pathogenic mechanism of
the various manifestations of the metabolic syndrome. Inﬂamma-
tion in the CNS seems to be earlier than peripheral derangements.
The TBK1/IKKε -NF-κB is the most reported central inﬂammation
pathway inducing the release of proinﬂammatory cytokines
during positive energy balance, leading to generation of type 2
diabetes. We contemplate that in later years, the molecular
routes, together with TBK1/IKKε-NF-κB, which contribute to the
regulation of the activation of NF-κB during obesity, will be
deciphered.105
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